tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Etzer Darout, 243 are a BUY (83.51%), 40 are a HOLD (13.75%), 8 are a SELL (2.75%).
Analyst Etzer Darout, currently employed at BARCLAYS, carries an average stock price target met ratio of 52.97% that have a potential upside of 41.98% achieved within 149 days. Previously, Etzer Darout worked at BMO.
Etzer Darout’s has documented 574 price targets and ratings displayed on 54 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on SMMT, Summit Therapeutics PLC.
Analyst best performing recommendations are on FPRX (FIVE PRIME THERAPEUTICS).
The best stock recommendation documented was for MGNX (MACROGENICS) at 7/11/2022. The price target of $4 was fulfilled within 2 days with a profit of $0.45 (12.68%) receiving and performance score of 63.38.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 07-Oct-2024
$12
$4.06 (51.13%)
$12
1 months 20 days ago
(11-Aug-2026)
2/8 (25%)
$5.13 (74.67%)
317
Buy Since 15-May-2020
$14
$6.06 (76.32%)
$14
6 months 1 days ago
(30-Mar-2026)
0/5 (0%)
$7.36 (110.84%)
Buy Since 30-Mar-2026
$25
$17.06 (214.86%)
$25
6 months 1 days ago
(30-Mar-2026)
0/2 (0%)
$18.36 (276.51%)
Buy Since 24-Apr-2024
$11
$3.06 (38.54%)
$8
1 years 2 months 13 days ago
(18-Jul-2025)
1/2 (50%)
$6.82 (163.16%)
579
Buy Since 21-Mar-2024
$6
$-1.94 (-24.43%)
$6
2 years 1 months 15 days ago
(16-Aug-2024)
3/6 (50%)
$2.4 (66.67%)
403
Which stock is Etzer Darout most bullish on?
Which stock is Etzer Darout most reserved on?
What Year was the first public recommendation made by Etzer Darout?
